+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oropharyngeal Cancer - Pipeline Review, H2 2019

  • ID: 4901268
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 485 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astex Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Gilead Sciences Inc
  • Incyte Corp
  • Merck & Co Inc
  • MORE
Oropharyngeal Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2019, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 17, 10 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astex Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Gilead Sciences Inc
  • Incyte Corp
  • Merck & Co Inc
  • MORE
Introduction
Oropharyngeal Cancer - Overview
Oropharyngeal Cancer - Therapeutics Development
Oropharyngeal Cancer - Therapeutics Assessment
Oropharyngeal Cancer - Companies Involved in Therapeutics Development
Oropharyngeal Cancer - Drug Profiles
Oropharyngeal Cancer - Dormant Projects
Oropharyngeal Cancer - Discontinued Products
Oropharyngeal Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Oropharyngeal Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Oropharyngeal Cancer - Pipeline by AbbVie Inc, H2 2019
Oropharyngeal Cancer - Pipeline by Advaxis Inc, H2 2019
Oropharyngeal Cancer - Dormant Projects, H2 2019
Oropharyngeal Cancer - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Oropharyngeal Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Advaxis Inc
  • AMI Onco Theranostics LLC
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Biomimetix JV LLC
  • Boehringer Ingelheim International GmbH
  • Brooklyn ImmunoTherapeutics LLC
  • Celldex Therapeutics Inc
  • Eisai Co Ltd
  • EpicentRx Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • IMV Inc
  • Incyte Corp
  • Innate Pharma SA
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Merck KGaA
  • Ono Pharmaceutical Co Ltd
  • PNP Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Shionogi & Co Ltd
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Transgene SA
  • Turnstone Biologics Inc
  • VasGene Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll